ARK5蛋白在上皮性卵巢癌细胞卡铂耐药中的作用

摘要
图/表
参考文献
相关文章 (2)

全文: PDF (1495 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探索上皮性卵巢癌细胞卡铂耐药的机制，以提高卵巢癌患者化疗的疗效。方法：应用CCK8法检测卡铂处理后的上皮性卵巢癌细胞增殖，Western blot法检测上皮间质化转变相关蛋白E-Cadherin和Vi-mentin表达情况，流式细胞技术检测细胞表面CD133的变化情况，使用siRNA敲降AMP激活的蛋白激酶家族成员5（ARK5）后再观察卡铂的作用。结果：上皮性卵巢癌细胞系SKOV3与A2780的卡铂IC50分别为2.824 µg/mL与1.760 µg/mL，并且卡铂能诱导上皮性卵巢癌细胞发生上皮间质化转变；卡铂诱导ARK5显著上调，而不影响SNF1/AMP激活的蛋白激酶表达，敲降ARK5基因能显著减弱卡铂诱导卵巢癌细胞产生上皮间质化转变的效果。结论：ARK5在上皮性卵巢癌细胞卡铂耐药机制中具有重要作用，降低ARK5的表达可以减弱卡铂诱导卵巢癌细胞上皮间质化转变的作用。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	潘洁雪
	林凤

关键词 ：上皮性卵巢癌, 上皮间质化转变, 卡铂, ARK5

Abstract：Objective: To investigate the mechanisms of carboplatin resistance in epithelial ovarian cancer (EOC) cells, and provide preliminary exploration on improving the effect of chemotherapy in ovarian cancer patients. Methods: Cell counting kit-8 was used to evaluate the effect of carboplatin on the proliferation of SKOV3 and A2780 cells, meanwhile the expression of epithelial-mesenchymal transition related proteins E-cadherin and vimentin were detected by Western blot. Flow cytometry assay was used to detect the expression of CD133. In addition, knockdown of ARK5 was to evaluate the role of ARK5 in the carboplatin-induced epithelial-mesenchymal transition. Results: The IC50 of carboplatin in SKOV3 and A2780 was 2.824 µg/mL and 1.760 µg/mL, respectively. Furthermore, we also found that carboplatin could significantly induce epithelial-mesenchymal transition in EOC cells. Carboplatin could increase the expression of ARK5, but not SNARK. Knockdown of ARK5 could attenuate the induction of epithelial-mesenchymal transition. Conclusion: ARK5 plays an important role in carboplatin resistance in EOC cells. Knockdown of ARK5 may reduce the carboplatin-induced epithelial-mesenchymal transition.

Key words： epithelial ovarian cancer cells epithelial-mesenchymal transition carboplatin ARK5

收稿日期: 2017-03-30

基金资助:浙江省中医药管理局青年人才基金项目（2017ZQ0 20）；浙江省医药卫生科技计划项目（2017KY462）；温州市科技局科研基金资助项目（Y20160037）。

通讯作者: 林凤，副主任医师，Email：234898067@qq.com

作者简介: 潘洁雪（1986-），女，浙江温州人，住院医师，博士。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2017/V47/I11/805

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
[2] ADAMS G, ZEKRI J, WONG H, et al. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?[J]. BJOG, 2010, 117(12): 1459-1467.
[3] KWON J S, MCGAHAN C, DEHAECK U, et al. The significance of combination chemotherapy in epithelial ovarian cancer[J]. Int J Gynecol Cancer, 2014, 24(2): 226-232.
[4] SUZUKI A, KUSAKAI G, KISHIMOTO A, et al. Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein[J]. J Biol Chem, 2003, 278(1): 48-53.
[5] SUZUKI A, KUSAKAI G, KISHIMOTO A, et al. ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation[J]. Oncogene, 2003, 22(40): 6177-6182.
[6] CHANG X Z, YU J, LIU H Y, et al. ARK5 is associated with the invasive and metastatic potential of human breast cancer cells[J]. J Cancer Res Clin Oncol, 2012, 138(2): 247-254.
[7] CUI J, YU Y, LU G F, et al. Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma[J]. Tumour Biol, 2013, 34(3): 1913-1918.
[8] PHIPPEN N T, BATEMAN N W, WANG G, et al. NUAK1 (ARK5) is associated with poor prognosis in vvarian can-cer[J]. Front Oncol, 2016, 6, 213.
[9] ZHANG H Y, LI J H, LI G, et al. Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer[J]. Oncol Rep, 2015, 34(3): 1193-1202.
[10] COLEMAN R L, MONK B J, SOOD A K, et al. Latest research and treatment of advanced-stage epithelial ovarian cancer[J]. Nat Rev Clin Oncol, 2013, 10(4): 211-224
[11] TEO M C. Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer[J]. Curr Opin Obstet Gynecol, 2014, 26(1): 3-8.
[12] JELOVAC D, ARMSTRONG D K. Recent progress in the diagnosis and treatment of ovarian cancer[J]. CA Cancer J Clin, 2011, 61(3): 183-203.
[13] FISCHER K R, DURRANS A, LEE S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance[J]. Nature, 2015, 527 (7579): 472-476.
[14] ZHENG X, CARSTENS J L, KIM J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer[J]. Nature, 2015, 527(7579): 525-530.
[15] 陈潇, 周浩, 周希, 等. 松弛素对TGF-β诱导的内皮细胞间质化的抑制作用[J]. 温州医科大学学报, 2014, 44(3): 161-165.
[16] DING Q, MIYAZAKI Y, TSUKASA K, et al. CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis[J]. Mol Cancer, 2014, 13, 15.
[17] PAN J X, WANG F, YE L Y. Doxorubicin-induced epithelial-mesenchymal transition through SEMA 4A in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2016, 479(4): 610-614.
[18] SUZUKI A, KUSAKAI G, KISHIMOTO A, et al. Regulation of caspase-6 and FLIP by the AMPK family member ARK5[J]. Oncogene, 2004, 23(42): 7067-7075.